South America Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Drug Formulation (Lyophilized Powder and Doxorubicin Injection), Application (Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)   

The SAM doxorubicin market is expected to grow from US$ 65.06 million in 2022 to US$ 86.34 million by 2028; it is estimated to grow at a CAGR of 4.8% from 2022 to 2028.

Both chemotherapy and targeted therapy significantly improve cancer patients' chances of survival and quality of life. These therapies may bring about the complete remission of a tumor. Owing to these benefits, the demand for chemotherapy has surged across the region. Advanced cancer treatments improve patient survival and increase long-term outpatient chemotherapy requirements. More exposure to chemotherapy results in a greater demand for doxorubicin drugs, thereby boosting the market growth across the region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the SAM doxorubicin market. The SAM doxorubicin market is expected to grow at a good CAGR during the forecast period. 

SAM Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)  

SAM Doxorubicin Market Segmentation                 

The SAM doxorubicin market is segmented based on drug formulation, application, distribution channel, and country. Based on drug formulation, the SAM doxorubicin market is bifurcated into lyophilized powder and doxorubicin injection. The lyophilized powder segment dominated the market in 2022. Based on application, the SAM doxorubicin market is segmented into breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, and others. The breast cancer segment dominated the market in 2022. Based on distribution channel, the SAM doxorubicin market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2022. Based on country, the SAM doxorubicin market has been categorized into Brazil, Argentina, and rest of SAM. Our regional analysis states that Brazil dominated the market in 2022.   

Accord Healthcare; Baxter International Inc.; Cipla Inc.; Dr. Reddy's Laboratories; Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.); Meiji Holdings Co., Ltd.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd; and Zydus Cadila are among the leading companies in the SAM doxorubicin market.  

1. Accord Healthcare
2. Baxter International Inc.
3. Cipla Inc.
4. Dr. Reddy's Laboratories
5. Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.)   
6. Meiji Holdings Co., Ltd.   
7. Novartis AG   
8. Pfizer Inc. 
9. Sun Pharmaceutical Industries Ltd
10. Zydus Cadila   

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM doxorubicin market.              
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the SAM doxorubicin market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the doxorubicin market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution